JPRN-UMIN000035414已完成未知
The effect of calcimimetics on complications of chronic kidney disease - The effect of calcimimetics on complications of chronic kidney disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
Etelcalcetide was administered to 32 hemodialysis patients with secondary hyperparathyroidism. iPTH, BAP, Osteocalcin, TRACP 5b, and FGF23 decreased significantly, and this decrease persisted.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis
研究者
相似试验
终止
不适用
Treatment of Secondary Hyperparathyroidism in the Uremic PatientSecondary HyperparathyroidismVitamin D DeficiencyChronic Kidney DiseaseNCT00469599Zealand University Hospital86
终止
1 期
Cinacalcet to Treat Hypercalcemia in Renal Transplant RecipientsSecondary HyperparathyroidismHypercalcemiaNCT00415584Montefiore Medical Center4
已完成
4 期
The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of ParathyroidHyperparathyroidism, SecondaryNCT02056730Chulalongkorn University60
已完成
4 期
Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysisSecondary hyperpapathyroidismJPRN-UMIN000033514Fujita Memorial Hospital, Department of Internal Medicine52
已完成
不适用
Evaluation of calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism: a real-world observational studyHemodialysis patients with secondary hyperparathyroidismJPRN-UMIN000030354Ono Pharmaceutical Co.,ltd.3,000